570 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Downtrend
Article Searches
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
3 Stocks With Big News Coming at ASCO 2019 https://www.fool.com/investing/2019/05/15/3-stocks-with-big-news-coming-at-asco-2019.aspx?source=iedfolrf0000001 May 15, 2019 - These cancer drug developers could report market-moving news soon.
Top Research Reports for Alphabet, Eli Lilly & CVS Health http://www.zacks.com/research-daily/413862/top-research-reports-for-alphabet-eli-lilly-cvs-health?cid=CS-ZC-FT-413862 May 14, 2019 - Top Research Reports for Alphabet, Eli Lilly & CVS Health
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-ZC-FT-413860 May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Why Are Investors Passing on Teva Pharmaceutical Industries? https://www.fool.com/investing/2019/05/05/why-are-investors-passing-on-teva-pharmaceutical-i.aspx?source=iedfolrf0000001 May 05, 2019 - Teva's turnaround won't kick into high gear anytime soon.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-ZC-FT-408333 May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-ZC-FT-408311 May 03, 2019 - Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat http://www.zacks.com/stock/news/407647/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-ZC-FT-407647 May 02, 2019 - United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/406364/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-406364 May 01, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Pages: 123456...57

Page 1>